BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Westgaard A, Pomianowska E, Clausen OP, Gladhaug IP. Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies? Ann Surg Oncol. 2013;20:430-439. [PMID: 22956064 DOI: 10.1245/s10434-012-2603-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Radojkovic M, Stojanovic M, Radojković D, Jeremic L, Mihailovic D, Ilic I. Histopathologic differentiation as a prognostic factor in patients with carcinoma of the hepatopancreatic ampulla of Vater. J Int Med Res 2018;46:4634-9. [PMID: 30027790 DOI: 10.1177/0300060518786920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Palmeri M, Funel N, Franco GD, Furbetta N, Gianardi D, Guadagni S, Bianchini M, Pollina LE, Ricci C, Chiaro MD, Candio GD, Morelli L. Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology. World J Gastroenterol 2020;26:6822-36. [PMID: 33268964 DOI: 10.3748/wjg.v26.i43.6822] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Hank T, Klaiber U, Sahora K, Schindl M, Strobel O. [Surgery for periampullary pancreatic cancer]. Chirurg 2021;92:776-87. [PMID: 34259884 DOI: 10.1007/s00104-021-01462-1] [Reference Citation Analysis]
4 Yamamoto K, Itoi T, Nagata N, Sofuni A, Tsuchiya T, Ishii K, Tanaka R, Tonozuka R, Honjo M, Mukai S, Asai Y, Matsunami Y, Yamaguchi H, Matsubayashi J, Joyama E, Nagakawa Y. Novel method for evaluating the indication for endoscopic papillectomy in patients with ampullary adenocarcinoma. Sci Rep 2021;11:600. [PMID: 33436750 DOI: 10.1038/s41598-020-79836-4] [Reference Citation Analysis]
5 Miyabe K, Notohara K, Asano G, Kachi K, Kato A, Natsume M, Jinno N, Hori Y, Yoshida M, Naitoh I, Hayashi K, Ohara H, Takahashi S, Kataoka H. Laterally Spreading Adenocarcinoma Involving the Lower Bile Duct and Duodenum Expressing Heterogeneous Immunohistochemical Phenotypes. Intern Med 2019;58:3087-92. [PMID: 31292382 DOI: 10.2169/internalmedicine.2801-19] [Reference Citation Analysis]
6 Zimmermann C, Wolk S, Aust DE, Meier F, Saeger HD, Ehehalt F, Weitz J, Welsch T, Distler M. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep. 2019;9:12676. [PMID: 31481741 DOI: 10.1038/s41598-019-49179-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
7 Okano K, Oshima M, Yachida S, Kushida Y, Kato K, Kamada H, Wato M, Nishihira T, Fukuda Y, Maeba T, Inoue H, Masaki T, Suzuki Y. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma. J Surg Oncol 2014;110:156-62. [PMID: 24619853 DOI: 10.1002/jso.23600] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
8 Schiergens TS, Reu S, Neumann J, Renz BW, Niess H, Boeck S, Heinemann V, Bruns CJ, Jauch KW, Kleespies A. Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. Surgery. 2015;158:151-161. [PMID: 25819575 DOI: 10.1016/j.surg.2015.02.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
9 Zhang L, DeMay RM. Cytological features of mixed adenoneuroendocrine carcinoma of the ampulla: two case reports with review of literature. Diagn Cytopathol. 2014;42:1075-1084. [PMID: 24554593 DOI: 10.1002/dc.23107] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
10 Al Abbas AI, Falvello V, Zenati M, Mani A, Hogg ME, Zeh HJ 3rd, Singhi A, Bahary N, Zureikat AH. Impact of adjuvant chemotherapy regimen on survival outcomes in immunohistochemical subtypes of ampullary carcinoma. J Surg Oncol. 2019. [PMID: 31840257 DOI: 10.1002/jso.25808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
11 Moekotte AL, Malleo G, van Roessel S, Bonds M, Halimi A, Zarantonello L, Napoli N, Dreyer SB, Wellner UF, Bolm L, Mavroeidis VK, Robinson S, Khalil K, Ferraro D, Mortimer MC, Harris S, Al-Sarireh B, Fusai GK, Roberts KJ, Fontana M, White SA, Soonawalla Z, Jamieson NB, Boggi U, Alseidi A, Shablak A, Wilmink JW, Primrose JN, Salvia R, Bassi C, Besselink MG, Abu Hilal M. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. Br J Surg 2020;107:1171-82. [PMID: 32259295 DOI: 10.1002/bjs.11555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Elebro J, Heby M, Warfvinge CF, Nodin B, Eberhard J, Jirström K. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PLoS One 2016;11:e0153533. [PMID: 27070783 DOI: 10.1371/journal.pone.0153533] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
13 Colussi O, Voron T, Pozet A, Hammel P, Sauvanet A, Bachet J, Vaillant J, Rougier P, Nordlinger B, Berger A, Coriat R, Dousset B, Malka D, André T, Paye F, Aparicio T, Locher C, Cojean Zeleck D, Tchinou L, Bonnetain F, Taieb J. Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort. European Journal of Surgical Oncology (EJSO) 2015;41:520-6. [DOI: 10.1016/j.ejso.2015.01.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
14 Lu JY, Yu H, Zou XL, Li Z, Hu XM, Shen YQ, Hu DY. Apparent diffusion coefficient-based histogram analysis differentiates histological subtypes of periampullary adenocarcinoma. World J Gastroenterol 2019; 25(40): 6116-6128 [PMID: 31686767 DOI: 10.3748/wjg.v25.i40.6116] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Chandrasegaram MD, Gill AJ, Samra J, Price T, Chen J, Fawcett J, Merrett ND. Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer. World J Gastrointest Oncol 2017; 9(10): 407-415 [PMID: 29085567 DOI: 10.4251/wjgo.v9.i10.407] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
16 Luchini C, Veronese N, Nottegar A, Riva G, Pilati C, Mafficini A, Stubbs B, Simbolo M, Mombello A, Corbo V, Cheng L, Yachida S, Wood LD, Lawlor RT, Salvia R, Scarpa A. Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. Pancreas 2019;48:70-6. [PMID: 30451797 DOI: 10.1097/MPA.0000000000001194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Harthimmer MR, Stolborg U, Pfeiffer P, Mortensen MB, Fristrup C, Detlefsen S. Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas. J Clin Pathol 2019;72:762-70. [DOI: 10.1136/jclinpath-2019-205912] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Feretis M, Wang T, Iype S, Duckworth A, Brais R, Basu B, Jamieson NV, Huguet E, Balakrishnan A, Jah A, Praseedom RK, Harper SJ, Liau SS. Development of a Prognostic Model That Predicts Survival After Pancreaticoduodenectomy for Ampullary Cancer. Pancreas 2017;46:1314-21. [PMID: 28902764 DOI: 10.1097/MPA.0000000000000929] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Guo M, Beal EW, Miller ED, Williams TM, Tsung A, Dillhoff M, Ejaz A, Pawlik TM, Cloyd JM. Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score-matched analysis of the NCDB. J Surg Oncol 2021;123:1558-67. [PMID: 33596343 DOI: 10.1002/jso.26435] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017;24:2031-2039. [PMID: 28124275 DOI: 10.1245/s10434-017-5777-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
21 Hamfjord J, Saldova R, Stöckmann H, Sandhu V, Bowitz Lothe IM, Buanes T, Lingjærde OC, Labori KJ, Rudd PM, Kure EH. Serum N -Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma. J Proteome Res 2015;14:5144-56. [DOI: 10.1021/acs.jproteome.5b00395] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
22 Kim HS, Jang JY, Yoon YS, Park SJ, Kwon W, Kim SW, Han HS, Han SS, Park JS, Yoon DS. Does adjuvant treatment improve prognosis after curative resection of ampulla of Vater carcinoma? A multicenter retrospective study. J Hepatobiliary Pancreat Sci 2020;27:721-30. [PMID: 32652820 DOI: 10.1002/jhbp.801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Bi L, Dong Y, Jing C, Wu Q, Xiu J, Cai S, Huang Z, Zhang J, Han X, Liu Q, Lv S. Differentiation of pancreatobiliary-type from intestinal-type periampullary carcinomas using 3.0T MRI. J Magn Reson Imaging. 2016;43:877-886. [PMID: 26395453 DOI: 10.1002/jmri.25054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
24 Balci S, Basturk O, Saka B, Bagci P, Postlewait LM, Tajiri T, Jang KT, Ohike N, Kim GE, Krasinskas A, Choi H, Sarmiento JM, Kooby DA, El-Rayes BF, Knight JH, Goodman M, Akkas G, Reid MD, Maithel SK, Adsay V. Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases. Ann Surg Oncol 2015;22:4392-401. [PMID: 25783680 DOI: 10.1245/s10434-015-4499-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
25 Leo JM, Kalloger SE, Peixoto RD, Gale NS, Webber DL, Owen DA, Renouf D, Schaeffer DF. Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups. J Clin Pathol. 2016;69:431-439. [PMID: 26500334 DOI: 10.1136/jclinpath-2015-203337] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
26 Mafficini A, Amato E, Cataldo I, Rusev BC, Bertoncello L, Corbo V, Simbolo M, Luchini C, Fassan M, Cantù C, Salvia R, Marchegiani G, Tortora G, Lawlor RT, Bassi C, Scarpa A. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. Ann Surg 2018;267:149-56. [PMID: 27611608 DOI: 10.1097/SLA.0000000000001999] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
27 Kapp M, Kosmala A, Kircher S, Luber V, Kunzmann V. Exceptional Response to Nanoparticle Albumin-Bound Paclitaxel and Gemcitabine in a Patient with a Refractory Adenocarcinoma of the Ampulla of Vater. Case Rep Oncol. 2016;9:15-24. [PMID: 26933414 DOI: 10.1159/000443304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
28 Clauss D, Tjaden C, Hackert T, Schneider L, Ulrich CM, Wiskemann J, Steindorf K. Cardiorespiratory fitness and muscle strength in pancreatic cancer patients. Support Care Cancer 2017;25:2797-807. [PMID: 28417202 DOI: 10.1007/s00520-017-3694-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
29 Doepker MP, Thompson ZJ, Centeno BA, Kim RD, Wong J, Hodul PJ. Clinicopathologic and survival analysis of resected ampullary adenocarcinoma. J Surg Oncol 2016;114:170-5. [PMID: 27158031 DOI: 10.1002/jso.24281] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
30 Nassour I, Mokdad AA, Minter RM, Polanco PM, Augustine MM, Mansour JC, Porembka MR, Wang SC. Racial and ethnic disparities in a national cohort of ampullary cancer patients. J Surg Oncol 2018;117:220-7. [PMID: 28968918 DOI: 10.1002/jso.24835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Fernández Moro C, Fernandez-Woodbridge A, Alistair D'souza M, Zhang Q, Bozoky B, Kandaswamy SV, Catalano P, Heuchel R, Shtembari S, Del Chiaro M, Danielsson O, Björnstedt M, Löhr JM, Isaksson B, Verbeke C, Bozóky B. Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification. PLoS One 2016;11:e0166067. [PMID: 27829047 DOI: 10.1371/journal.pone.0166067] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
32 Erdmann JI, Eskens FA, Vollmer CM, Kok NF, Groot Koerkamp B, Biermann K, van Eijck CH. Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment. Ann Surg Oncol. 2015;22:2401-2407. [PMID: 25503345 DOI: 10.1245/s10434-014-4267-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
33 Asano E, Okano K, Oshima M, Kagawa S, Kushida Y, Munekage M, Hanazaki K, Watanabe J, Takada Y, Ikemoto T, Shimada M, Suzuki Y; On behalf of the Shikoku Consortium of Surgical Research (SCSR). Phenotypic characterization and clinical outcome in ampullary adenocarcinoma: Characterization of Ampullary Cancer. J Surg Oncol 2016;114:119-27. [DOI: 10.1002/jso.24274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
34 Lai ZW, Bolm L, Fuellgraf H, Biniossek ML, Makowiec F, Hopt UT, Werner M, Keck T, Bausch D, Sorio C, Scarpa A, Schilling O, Bronsert P, Wellner UF. Characterization of various cell lines from different ampullary cancer subtypes and cancer associated fibroblast-mediated responses. BMC Cancer 2016;16:195. [PMID: 26951071 DOI: 10.1186/s12885-016-2193-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
35 Chavez M, Sharpe J, O'brien T, Patton K, Portnoy D, Vanderwalde N, Deneve J, Shibata D, Behrman S, Dickson P. Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma. The American Journal of Surgery 2017;214:856-61. [DOI: 10.1016/j.amjsurg.2017.01.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
36 Elebro J, Heby M, Gaber A, Nodin B, Jonsson L, Fristedt R, Uhlén M, Jirström K, Eberhard J. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. J Transl Med 2014;12:289. [PMID: 25323550 DOI: 10.1186/s12967-014-0289-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
37 Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH. Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas. Mol Oncol 2015;9:758-71. [PMID: 25579086 DOI: 10.1016/j.molonc.2014.12.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
38 Okano K, Oshima M, Suto H, Ando Y, Asano E, Kamada H, Kobara H, Masaki T, Suzuki Y. Ampullary carcinoma of the duodenum: current clinical issues and genomic overview. Surg Today 2021. [PMID: 33797636 DOI: 10.1007/s00595-021-02270-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Xue Y, Reid MD. Approaches to Biopsy and Resection Specimens from the Ampulla. Surg Pathol Clin 2020;13:453-67. [PMID: 32773194 DOI: 10.1016/j.path.2020.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Bronsert P, Kohler I, Werner M, Makowiec F, Kuesters S, Hoeppner J, Hopt UT, Keck T, Bausch D, Wellner UF. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin. BMC Cancer. 2013;13:428. [PMID: 24053229 DOI: 10.1186/1471-2407-13-428] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
41 Bowitz Lothe IM, Kleive D, Pomianowska E, Cvancarova M, Kure E, Dueland S, Gladhaug IP, Labori KJ. Clinical relevance of pancreatobiliary and intestinal subtypes of ampullary and duodenal adenocarcinoma: Pattern of recurrence, chemotherapy, and survival after pancreatoduodenectomy. Pancreatology 2019;19:316-24. [PMID: 30713128 DOI: 10.1016/j.pan.2019.01.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Kumari N, Prabha K, Singh RK, Baitha DK, Krishnani N. Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry. Hum Pathol. 2013;44:2213-2219. [PMID: 23834763 DOI: 10.1016/j.humpath.2013.05.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
43 Meijer LL, Strijker M, de Bakker JK, Toennaer JG, Zonderhuis BM, van der Vliet HJ, Wilmink H, Verheij J, Daams F, Busch OR, van Grieken NC, Besselink MG, Kazemier G. Clinical outcomes of patients with duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma. World J Gastrointest Oncol 2020; 12(3): 347-357 [PMID: 32206184 DOI: 10.4251/wjgo.v12.i3.347] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Gingras MC, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot E, Dewal N. Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep. 2016;14:907-919. [PMID: 26804919 DOI: 10.1016/j.celrep.2015.12.005] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
45 Ma H, Xiao W, Wang M, Shi X. CDH17+/CDX2+ Can be Helpful in Providing Support for Small Intestinal Origin Versus Pancreatic or Biliary Origin. Appl Immunohistochem Mol Morphol 2021;29:541-5. [PMID: 33958523 DOI: 10.1097/PAI.0000000000000913] [Reference Citation Analysis]
46 Reid MD, Balci S, Ohike N, Xue Y, Kim GE, Tajiri T, Memis B, Coban I, Dolgun A, Krasinskas AM, Basturk O, Kooby DA, Sarmiento JM, Maithel SK, El-Rayes BF, Adsay V. Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. Mod Pathol. 2016;29:1575-1585. [PMID: 27586202 DOI: 10.1038/modpathol.2016.124] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
47 Affi Koprowski M, Sutton TL, Brinkerhoff BT, Grossberg A, Sheppard BC, Mayo SC. Oncologic outcomes in resected ampullary cancer: Relevance of histologic subtype and adjuvant chemotherapy. Am J Surg 2021;221:1128-34. [PMID: 33883071 DOI: 10.1016/j.amjsurg.2021.04.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Yamamoto K, Iwasaki E, Itoi T. Insights and updates on endoscopic papillectomy. Expert Rev Gastroenterol Hepatol. 2020;14:435-444. [PMID: 32380873 DOI: 10.1080/17474124.2020.1766965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Serikuly E, Makhanbetkhan SS, Baymakhanov ZB, Kaniev SA, Doskhanov MO, Chormanov AT, Seysembaev MA, Baymakhanov BB. [Comparative analysis of radical surgical treatment of periampullary tumors]. Khirurgiia (Mosk) 2020;:24-9. [PMID: 32352664 DOI: 10.17116/hirurgia202004124] [Reference Citation Analysis]
50 Pomianowska E, Schjølberg AR, Clausen OP, Gladhaug IP. COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis. BMC Cancer 2014;14:458. [PMID: 24950702 DOI: 10.1186/1471-2407-14-458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
51 Schiergens TS, Renz BW, Reu S, Neumann J, Al-sayegh R, Nieß H, Ilmer M, Kruger S, Boeck S, Heinemann V, Werner J, Kleespies A. Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer. J Gastrointest Surg 2017;21:1775-83. [DOI: 10.1007/s11605-017-3489-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
52 Maguire A, Sheahan K. Primary small bowel adenomas and adenocarcinomas-recent advances. Virchows Arch 2018;473:265-73. [PMID: 29998424 DOI: 10.1007/s00428-018-2400-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
53 Jeong BK, Sung YN, Kim SJ, An S, Park H, Hwang HS, Kang HJ, Lee JH, Song KB, Kim KP, Hwang DW, Lee SS, Kim SC, Hong SM. High-grade precursor lesions can be used as surrogate markers to identify the epicenter of periampullary carcinomas. Hum Pathol 2019;84:92-104. [PMID: 30261192 DOI: 10.1016/j.humpath.2018.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Zhou Y, Li D, Wu L, Si X. The histopathologic type predicts survival of patients with ampullary carcinoma after resection: A meta-analysis. Pancreatology 2017;17:273-8. [DOI: 10.1016/j.pan.2017.01.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
55 Xue Y, Vanoli A, Balci S, Reid MM, Saka B, Bagci P, Memis B, Choi H, Ohike N, Tajiri T, Muraki T, Quigley B, El-rayes BF, Shaib W, Kooby D, Sarmiento J, Maithel SK, Knight JH, Goodman M, Krasinskas AM, Adsay V. Non-ampullary–duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. Mod Pathol 2017;30:255-66. [DOI: 10.1038/modpathol.2016.174] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
56 Meijer LL, Alberga AJ, de Bakker JK, van der Vliet HJ, Le Large TYS, van Grieken NCT, de Vries R, Daams F, Zonderhuis BM, Kazemier G. Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2018;25:2681-2692. [PMID: 29946997 DOI: 10.1245/s10434-018-6567-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
57 Hong SS, Han SS, Kwon W, Jang JY, Kim HJ, Cho CK, Ahn KS, Yang JD, Park Y, Min SK, Moon JI, Roh YH, Lee SE, Park JS, Kim SG, Jeong CY, Heo JS, Hwang HK. Comparison of Oncologic Outcomes between Transduodenal Ampullectomy and Pancreatoduodenectomy in Ampulla of Vater Cancer: Korean Multicenter Study. Cancers (Basel) 2021;13:2038. [PMID: 33922504 DOI: 10.3390/cancers13092038] [Reference Citation Analysis]
58 Buanes TA. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research. World J Gastroenterol 2016; 22(48): 10502-10511 [PMID: 28082802 DOI: 10.3748/wjg.v22.i48.10502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
59 Kim D, Giorgadze T, Goyal A. Cytologic features of pancreatobiliary neoplasm of duodenum. Diagn Cytopathol 2019;47:1059-62. [PMID: 31276311 DOI: 10.1002/dc.24271] [Reference Citation Analysis]
60 Shaib WL, Sharma R, Brutcher E, Kim S, Maithel SK, Chen Z, Kooby DA, Kauh J, Landry J, El-rayes BF. Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma: Treatment Utilization and Surgical Outcome. J Surg Oncol 2014;109:556-60. [DOI: 10.1002/jso.23529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
61 Cen P, Wray CJ, Zhang S, Thosani NC, Dinh BC, Gonzalez A, Mohlere V, Bynon JS. Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination. Cancer Med 2019;8:3464-70. [PMID: 31102323 DOI: 10.1002/cam4.2181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Bi L, Yang L, Ma J, Cai S, Li L, Huang C, Xu J, Wang X, Huang M. Dynamic contract-enhanced CT-based radiomics for differentiation of pancreatobiliary-type and intestinal-type periampullary carcinomas. Clin Radiol 2021:S0009-9260(21)00444-X. [PMID: 34753589 DOI: 10.1016/j.crad.2021.09.010] [Reference Citation Analysis]
63 Nagarkar R, Patil D, Limaye S, Devhare P, Ghaisas A, Srivastava N, Apurwa S, Patil S, John J, Raazi Z, Shreenivas A, Sambath J, Srinivasan A, Kumar P, Akolkar D, Datar R. Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy. Oncotarget 2020;11:4195-200. [PMID: 33227091 DOI: 10.18632/oncotarget.27793] [Reference Citation Analysis]